Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease... see more

TSX:SZLS - Post Discussion

StageZero Life Sciences Ltd > ichor and szls in the news
View:
Post by Kaddyshack on Jan 18, 2021 1:25pm

ichor and szls in the news

https://calgaryherald.com/business/commercial-real-estate/private-lab-services-firm-pivots-to-help-with-covid-testing?fbclid=IwAR0iCQbRR7hYj5fx1RmXKkHFjfBAWkSXeJQBpwz8sjspXpgvnWeN3ldocLM

Nice little write up on Ichor and SZLS... great story on how Ichor came to be for those interested..
Comment by Saaweeeetdreams on Jan 18, 2021 1:44pm
I wonder if SZLS has reached out to any publications, TV, Radio, anything regarding the FIRST ever LAUNCH of an early detection cancer through Liquid Biopsy.  Today, more than 100,000 patients in the U.S. have benefited from the ColonSentry test. Our next generation test, Aristotle, uses proven technology to test for ten cancers from a single blood sample. Aristotle has high ...more  
Comment by LithLover on Jan 18, 2021 2:06pm
I would hope that is what the $1.5-2.0 million in marketing will be used for when they launch.  It should be everywhere.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities
USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse